Comparison of HercepTest (TM) mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status-MedSci.cn

Comparison of HercepTest (TM) mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status

Ruschoff, J; Friedrich, M; Nagelmeier, I; Kirchner, M; Andresen, LM; Salomon, K; Portier, B; Sredni, ST; Schildhaus, HU; Jasani, B; Grzelinski, M; Viale, G

Ruschoff, J (通讯作者)，Targos, Discovery Life Sci Co, Germaniastr 7, D-34119 Kassel, Germany.

VIRCHOWS ARCHIV, 2022; 481 (5): 685

Abstract

Performance of the new CE-IVD-marked HercepTest (TM) mAb pharmDx (Dako Omnis) assay (HercepTest (mAb)) was compared against the PATHWAY (R) anti-HER-2......

Full Text Link